TY - JOUR
T1 - Implantation of cardiac electronic devices in active COVID-19 patients
T2 - Results from an international survey
AU - Tovia-Brodie, Oholi
AU - Rav Acha, Moshe
AU - Belhassen, Bernard
AU - Gasperetti, Alessio
AU - Schiavone, Marco
AU - Forleo, Giovanni Battista
AU - Guevara-Valdivia, Milton E
AU - Ruiz, David Valdeolivar
AU - Lellouche, Nicolas
AU - Hamon, David
AU - Castagno, Davide
AU - Bellettini, Matteo
AU - De Ferrari, Gaetano M
AU - Laredo, Mikael
AU - Carvès, Jean-Baptiste
AU - Ignatiuk, Barbara
AU - Pasquetto, Giampaolo
AU - De Filippo, Paolo
AU - Malanchini, Giovanni
AU - Pavri, Behzad B
AU - Raphael, Craig
AU - Rivetti, Luigi
AU - Mantovan, Roberto
AU - Chinitz, Jason
AU - Harding, Melissa
AU - Boriani, Giuseppe
AU - Casali, Edoardo
AU - Wan, Elaine Y
AU - Biviano, Angelo
AU - Macias, Carlos
AU - Havranek, Stepan
AU - Lazzerini, Pietro Enea
AU - Canu, Antonio M
AU - Zardini, Marco
AU - Conte, Giulio
AU - Cano, Óscar
AU - Casella, Michela
AU - Rudic, Boris
AU - Omelchenko, Alexander
AU - Mathuria, Nilesh
AU - Upadhyay, Gaurav A
AU - Danon, Asaf
AU - Schwartz, Arie Lorin
AU - Maury, Philippe
AU - Nakahara, Shiro
AU - Goldenberg, Gustavo
AU - Schaerli, Nicolas
AU - Bereza, Sergiy
AU - Auricchio, Angelo
AU - Glikson, Michael
AU - Michowitz, Yoav
N1 - Copyright © 2021 Heart Rhythm Society. All rights reserved.
PY - 2022/2
Y1 - 2022/2
N2 - BACKGROUND: Cardiac implantable electronic device (CIED) implantation rates as well as the clinical and procedural characteristics and outcomes in patients with known active coronavirus disease 2019 (COVID-19) are unknown.OBJECTIVE: The purpose of this study was to gather information regarding CIED procedures during active COVID-19, performed with personal protective equipment, based on an international survey.METHODS: Fifty-three centers from 13 countries across 4 continents provided information on 166 patients with known active COVID-19 who underwent a CIED procedure.RESULTS: The CIED procedure rate in 133,655 hospitalized COVID-19 patients ranged from 0 to 16.2 per 1000 patients (P <.001). Most devices were implanted due to high-degree/complete atrioventricular block (112 [67.5%]) or sick sinus syndrome (31 [18.7%]). Of the 166 patients in the study survey, the 30-day complication rate was 13.9% and the 180-day mortality rate was 9.6%. One patient had a fatal outcome as a direct result of the procedure. Differences in patient and procedural characteristics and outcomes were found between Europe and North America. An older population (76.6 vs 66 years; P <.001) with a nonsignificant higher complication rate (16.5% vs 7.7%; P = .2) was observed in Europe vs North America, whereas higher rates of critically ill patients (33.3% vs 3.3%; P <.001) and mortality (26.9% vs 5%; P = .002) were observed in North America vs Europe.CONCLUSION: CIED procedure rates during known active COVID-19 disease varied greatly, from 0 to 16.2 per 1000 hospitalized COVID-19 patients worldwide. Patients with active COVID-19 infection who underwent CIED implantation had high complication and mortality rates. Operators should take these risks into consideration before proceeding with CIED implantation in active COVID-19 patients.
AB - BACKGROUND: Cardiac implantable electronic device (CIED) implantation rates as well as the clinical and procedural characteristics and outcomes in patients with known active coronavirus disease 2019 (COVID-19) are unknown.OBJECTIVE: The purpose of this study was to gather information regarding CIED procedures during active COVID-19, performed with personal protective equipment, based on an international survey.METHODS: Fifty-three centers from 13 countries across 4 continents provided information on 166 patients with known active COVID-19 who underwent a CIED procedure.RESULTS: The CIED procedure rate in 133,655 hospitalized COVID-19 patients ranged from 0 to 16.2 per 1000 patients (P <.001). Most devices were implanted due to high-degree/complete atrioventricular block (112 [67.5%]) or sick sinus syndrome (31 [18.7%]). Of the 166 patients in the study survey, the 30-day complication rate was 13.9% and the 180-day mortality rate was 9.6%. One patient had a fatal outcome as a direct result of the procedure. Differences in patient and procedural characteristics and outcomes were found between Europe and North America. An older population (76.6 vs 66 years; P <.001) with a nonsignificant higher complication rate (16.5% vs 7.7%; P = .2) was observed in Europe vs North America, whereas higher rates of critically ill patients (33.3% vs 3.3%; P <.001) and mortality (26.9% vs 5%; P = .002) were observed in North America vs Europe.CONCLUSION: CIED procedure rates during known active COVID-19 disease varied greatly, from 0 to 16.2 per 1000 hospitalized COVID-19 patients worldwide. Patients with active COVID-19 infection who underwent CIED implantation had high complication and mortality rates. Operators should take these risks into consideration before proceeding with CIED implantation in active COVID-19 patients.
KW - Aged
KW - Atrioventricular Block/epidemiology
KW - COVID-19/diagnosis
KW - Comorbidity
KW - Defibrillators, Implantable/statistics & numerical data
KW - Female
KW - Global Health/statistics & numerical data
KW - Humans
KW - Infection Control/instrumentation
KW - Male
KW - Middle Aged
KW - Mortality
KW - Outcome Assessment, Health Care
KW - Pacemaker, Artificial/statistics & numerical data
KW - Postoperative Complications/diagnosis
KW - Prosthesis Implantation/adverse effects
KW - Risk Factors
KW - SARS-CoV-2/isolation & purification
KW - Sick Sinus Syndrome/epidemiology
KW - Surveys and Questionnaires
UR - http://www.scopus.com/inward/record.url?scp=85120168356&partnerID=8YFLogxK
U2 - 10.1016/j.hrthm.2021.10.020
DO - 10.1016/j.hrthm.2021.10.020
M3 - Article
C2 - 34710561
VL - 19
SP - 206
EP - 216
JO - Heart Rhythm
JF - Heart Rhythm
SN - 1547-5271
IS - 2
ER -